Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lactate has been shown to offer neuroprotection in several pathologic conditions. This beneficial effect has been attributed to its use as an alternative energy substrate. However, recent description of the expression of the
HCA1
receptor for lactate in the central nervous system calls for reassessment of the mechanism by which lactate exerts its neuroprotective effects. Here, we show that
HCA1
receptor expression is enhanced 24 hours after reperfusion in an middle cerebral artery occlusion
stroke
model, in the ischemic cortex. Interestingly, intravenous injection of L-lactate at reperfusion led to further enhancement of
HCA1
receptor expression in the cortex and striatum. Using an in vitro oxygen-glucose deprivation model, we show that the
HCA1
receptor agonist 3,5-dihydroxybenzoic acid reduces cell death. We also observed that D-lactate, a reputedly non-metabolizable substrate but partial
HCA1
receptor agonist, also provided neuroprotection in both in vitro and in vivo ischemia models. Quite unexpectedly, we show D-lactate to be partly extracted and oxidized by the rodent brain. Finally, pyruvate offered neuroprotection in vitro whereas acetate was ineffective. Our data suggest that L- and D-lactate offer neuroprotection in ischemia most likely by acting as both an
HCA1
receptor agonist for non-astrocytic (most likely neuronal) cells as well as an energy substrate.
...
PMID:A probable dual mode of action for both L- and D-lactate neuroprotection in cerebral ischemia. 2603 41